Larimar Therapeutics, Inc. cotiza a 2.15 USD y tiene una capitalización bursátil de $224M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressiv…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.30 | $-0.31 | $-0.73 |
| Estimado | $-0.35 | $-0.38 | $-0.59 | $-0.55 |
| Sorpresa | — | +21.1% | +47.5% | -32.7% |
| Métrica | LRMR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -212.2% | -40.4% | -171.8% |
| ROA | -113.6% | -32.0% | -81.6% |
| Current Ratio | 2.19 | 2.84 | -0.65 |
| Debt / Equity | — | 0.28 | — |